Top Suppliers:I want be here
Related CAS#:
2137806-86-9 2680882-16-8
55038-10-3 2680864-53-1
2680694-46-4 2680718-71-0
2680899-18-5 2680707-21-3
2680818-79-3 2680901-69-1

1197-18-8

1197-18-8 structure
1197-18-8 structure
  • Name: Tranexamic acid
  • Chemical Name: tranexamic acid
  • CAS Number: 1197-18-8
  • Molecular Formula: C8H15NO2
  • Molecular Weight: 157.210
  • Catalog: Chemical reagent Organic reagent fatty acid
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2026-07-01 07:34:57
  • Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Target: OthersTranexamic acid is a synthetic derivative of the amino acid lysine. Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Its oral form is now being evaluated for use in outpatient conditions involving heavy bleeding.Toxicity/Adverse event: Rare in general, including gastrointestinal effects, dizziness, fatigue, headache, and hypersensitivity reactions. Use of tranexamic acid has a potential risk of thrombosis.
Name tranexamic acid
Synonyms tamcha
trans-p-(aminomethyl)cyclohexanecboxylicacid
Amstat
anvitoff
trans-4-(Aminomethyl)cyclohexancboxylic Acid
cl65336
Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-, hydrochloride (1:1)
UNII:9N7R477WCK
trans-cyclohexanecboxylicaci
Tranexamic Acid
transamcha
hexapromin
spiramin
TIMTEC-BB SBB006715
cyklokapron
tranexan
trans-4-aminoethylcyclohexane-1-cboxylicacid
trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
TranexaMic acid COS
Cyclohexanecboxylic acid, 4-(aminomethyl)-, trans
hexatron
TRANS-4-(AMINOMETHYL)CYCLOHEXANECBOXYLIC ACID
trasamlon
cis-4-(Aminomethyl)-1-cyclohexanecarboxylicacid
trans-4-aminomethylcyclohexane-1-cboxylate
trans-cyclohexanecboxylic acid
Tranesamicacid
transamlon
CIS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLICACID
LGB TA
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
Zatanax
MFCD00001466
trans-1-aminomethylcyclohexane-4-cboxylicacid
amstat
Tranexamic acid, (Titration: Dried basis)
EINECS 214-818-2
TranexaMic Acid-13C2, 15N
(1R,2R)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride (1:1)
trans-Tramadol hydrochloride
cyclocapron
trans-4-(AMinoMethyl)cyclohexanecboxylic acid, R
transamin
ugurol
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
dv-79
exacyl
trans-4-aminomethylcyclohexane-1-cboxylicacid
bay3517
TranexaMic acid BP JP
rp18
Tramadol hydrochloride
tranhexamicacid
hydroxypropylcyclodextrin,tranexamicacid
Tranexamic EP Impurity B
frenolyse
trans -4-Aminomethyl-1- cyclohexanecboxylic Acid [Tranexamic Acid]
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride
Tramadol HCL
(1R,2R)-2-[(diméthylamino)méthyl]-1-(3-méthoxyphényl)cyclohexanol chlorhydrate
AMCA,AMCHA,HAKU
Amstat, Tranexamic acid, trans-4-(Aminomethyl)cyclohexanecboxylic acid
cis-Tranexamic Acid
(+)-tramadol hydrochloride
Tranexamic acid [USAN::INN:BAN:JAN]
rikavin
amikapron
TranexaMic acid amstat
4-(ammoniomethyl)-1-cyclohexanecboxylate
Tranexamic
TRANS-4-AMINOMETHYL-1-CYCLOHEXANECBOXYLIC ACID
TRANS-4-(AMINOMETHYL)CYCLOHEXANECBOXYLIC ACID (TRANEXAMIC ACID)
emorhalt
cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-, hydrochloride
tranex
amcha
trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
Description Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Target: OthersTranexamic acid is a synthetic derivative of the amino acid lysine. Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Its oral form is now being evaluated for use in outpatient conditions involving heavy bleeding.Toxicity/Adverse event: Rare in general, including gastrointestinal effects, dizziness, fatigue, headache, and hypersensitivity reactions. Use of tranexamic acid has a potential risk of thrombosis.
Related Catalog
References

[1]. Bhat A, et al. Tranexamic acid overdosage-induced generalized seizure in renal failure. Saudi J Kidney Dis Transpl. 2014 Jan-Feb;25(1):130-2.

[2]. Couturier R, et al. Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing cardiac surgery with cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2014 Jan 13.
Density 1.1±0.1 g/cm3
Boiling Point 300.2±15.0 °C at 760 mmHg
Melting Point >300 °C(lit.)
Molecular Formula C8H15NO2
Molecular Weight 157.210
Flash Point 135.4±20.4 °C
Exact Mass 157.110275
PSA 63.32000
LogP 0.31
Vapour Pressure 0.0±1.3 mmHg at 25°C
Index of Refraction 1.497
Water Solubility 1G/6ML

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GU8400000
CHEMICAL NAME :
Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-
CAS REGISTRY NUMBER :
1197-18-8
BEILSTEIN REFERENCE NO. :
2207452
LAST UPDATED :
199612
DATA ITEMS CITED :
13
MOLECULAR FORMULA :
C8-H15-N-O2
MOLECULAR WEIGHT :
157.24
WISWESSER LINE NOTATION :
L6TJ AVQ D1Z -T

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4620 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher information, see PHTOEH Volume(issue)/page/year: 22,340,1965
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
4200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
85IRAK "Modern Pharmaceuticals of Japan, V," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1975 Volume(issue)/page/year: -,108,1975
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
5310 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1350 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
1110 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,512,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - chicken
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,389,1971 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
624 gm/kg/26W-I
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,395,1971 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
305 gm/kg
SEX/DURATION :
female 40 day(s) pre-mating female 1-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
REFERENCE :
APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher information, see PHTOEH Volume(issue)/page/year: 22,340,1965
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
9 mg/kg
SEX/DURATION :
female 9-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,415,1971
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
9 mg/kg
SEX/DURATION :
female 7-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,415,1971
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319-H335
Precautionary Statements P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi:Irritant;
Risk Phrases R36/37/38
Safety Phrases 26-36-37/39
RIDADR UN 1993 3/PG 2
WGK Germany 2
RTECS GU8400000
Packaging Group II
Hazard Class 3
HS Code 2922499990
19145-95-0 structure

19145-95-0

~%

1197-18-8 structure

1197-18-8

Literature: US3950405 A1, ;
953817-12-4 structure

953817-12-4

~%

108-31-6 structure

108-31-6

1197-18-8 structure

1197-18-8

Literature: Journal of Computer-Aided Molecular Design, , vol. 27, # 7 p. 615 - 635
HS Code 2922499990
Summary HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:1197-18-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1197-18-8 | Chemsrc address: https://m.chemsrc.com/en/baike/329852.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved